source
- Roivant’s inhaled pulmonary hypertension drug mosliciguat shows strong Phase 2 resultsRoivant invested $14 million in Bayer's inhaled soluble guanylate cyclase activator mosliciguat after a $294 million biobucks agreement in 2024, and promptly advanced the candidate into a Phase 2 s…
- Ionis secures FDA approval for zilganersen, a first treatment for Alexander diseaseIonis Pharmaceuticals announced that the U.S. Food and Drug Administration has approved its antisense drug zilganersen for the treatment of Alexander disease, an ultra‑rare neurodegenerative disord…